不遵守抗痴呆药物和相关因素:一项基于西班牙人口的注册数据研究
Eduardo Gutiérrez-Abejón1,2,3,4, M Aránzazu Pedrosa-Naudín3, Diego Fernández-Lázaro5,6
1Pharmacological Big Data Laboratory, Department of Cell Biology, Genetics, Histology and Pharmacology, Faculty of Medicine, University of Valladolid, Valladolid, Spain.
Frontiers in pharmacology
|November 20, 2024
概括
在西班牙,六分之一的痴呆症患者不坚持服用抗痴呆药物. 患有心脏代谢疾病的年轻男性风险最高,而医疗机构对药物不服药提供了一定程度的保护.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 痴呆症是老年人中越来越多的残疾原因,导致药物不服药.
- 失守会增加痴呆症患者的发病率,死亡率和医疗费用.
- 了解不坚持的预测因素对于改善患者的治疗结果至关重要.
研究的目的:
- 为了确定不坚持服用抗痴呆药物的患病率.
- 确定预测不遵守的社会人口统计学和健康相关因素.
- 为改善痴呆症护理中的药物坚持改善策略提供信息.
主要方法:
- 在西班牙的卡斯蒂利亚和莱昂 (西班牙) 进行基于人口的注册表研究 (2022年).
- 包括17563名使用抗痴呆药物的痴呆症患者.
- 使用药物占有率 (MPR>80%) 和用于预测分析的逻辑回归来测量坚持.
主要成果:
- 不坚持的患病率为16.67% (六分之一的患者).
- 患有心脏代谢疾病的年轻男性患者更有可能不坚持.
- 里瓦斯蒂格明 (19%) 和多内佩西尔 (17%) 的不依附率高于记忆素 (13.23%).
结论:
- 在西班牙,对抗痴呆症药物的不服药是一个重大问题.
- 诸如年龄较小,男性性别和心脏代谢疾病等因素预测不坚持.
- 机构化是一个保护因素,尽管即使在养老院里,不遵守仍然存在.
相关概念视频
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Dementia
96
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
96
Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Factors Affecting Drug Response: Overview
1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Parkinson's Disease: Treatment
220
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
220


